Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP825017.RApZAekuMXjKMWQpeCrgrjJ6UJlZY-9wK4ni0dA1kyLFE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP825017.RApZAekuMXjKMWQpeCrgrjJ6UJlZY-9wK4ni0dA1kyLFE130_assertion type Assertion NP825017.RApZAekuMXjKMWQpeCrgrjJ6UJlZY-9wK4ni0dA1kyLFE130_head.
- NP825017.RApZAekuMXjKMWQpeCrgrjJ6UJlZY-9wK4ni0dA1kyLFE130_assertion description "[EGFR activation is both a key molecular driver of disease progression and the target of a broad class of molecular agents designed to treat advanced cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP825017.RApZAekuMXjKMWQpeCrgrjJ6UJlZY-9wK4ni0dA1kyLFE130_provenance.
- NP825017.RApZAekuMXjKMWQpeCrgrjJ6UJlZY-9wK4ni0dA1kyLFE130_assertion evidence source_evidence_literature NP825017.RApZAekuMXjKMWQpeCrgrjJ6UJlZY-9wK4ni0dA1kyLFE130_provenance.
- NP825017.RApZAekuMXjKMWQpeCrgrjJ6UJlZY-9wK4ni0dA1kyLFE130_assertion SIO_000772 22653055 NP825017.RApZAekuMXjKMWQpeCrgrjJ6UJlZY-9wK4ni0dA1kyLFE130_provenance.
- NP825017.RApZAekuMXjKMWQpeCrgrjJ6UJlZY-9wK4ni0dA1kyLFE130_assertion wasDerivedFrom befree-20140225 NP825017.RApZAekuMXjKMWQpeCrgrjJ6UJlZY-9wK4ni0dA1kyLFE130_provenance.
- NP825017.RApZAekuMXjKMWQpeCrgrjJ6UJlZY-9wK4ni0dA1kyLFE130_assertion wasGeneratedBy ECO_0000203 NP825017.RApZAekuMXjKMWQpeCrgrjJ6UJlZY-9wK4ni0dA1kyLFE130_provenance.